<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34826519</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0984</ISSN><JournalIssue CitedMedium="Internet"><Volume>300</Volume><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of virological methods</Title><ISOAbbreviation>J Virol Methods</ISOAbbreviation></Journal><ArticleTitle>Comparison of the neutralizing activities of antibodies in clinical sera against both Sabin and wild-type polio pseudoviruses.</ArticleTitle><Pagination><StartPage>114376</StartPage><MedlinePgn>114376</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jviromet.2021.114376</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-0934(21)00315-3</ELocationID><Abstract><AbstractText>The cost-effectiveness of the Sabin inactivated poliovirus vaccine derived from the Sabin strains (S-IPV) and its reduced biosecurity risks during its manufacture make it the vaccine of choice over the IPVs derived from wild-type polioviruses. However, it is difficult to evaluate whether S-IPVs can achieve wild-type poliovirus containment in China, making its development there less attractive. To facilitate the development and adoption of S-IPVs in China, the aim of this study was to develop an alternative neutralizing assay using either a polio pseudovirus derived from a Sabin strain (S-pNA) or one derived from a wild-type strain (w-pNA) to replace the conventional neutralizing assay which uses live polioviruses. A total of 100 sera were collected from children immunized with an oral poliovirus vaccine and their antibody titers were assessed by both the S-pNA and w-pNA. The results showed that this method was feasible for the quantification of neutralizing antibody activities in the sera of the vaccinated individuals. The Wilcoxon signed-rank sum test indicated that the neutralizing antibody titers obtained against the Sabin strains were higher than those obtained with the wild-type strains for types 1 and 3, while for type 2, the titers against the wild-type strains were higher than those against the Sabin strains (p &lt; 0.001 for all three types). It is hoped that this assay could be used to assess whether immune sera by the S-IPV possess adequate neutralizing capacity against both attenuated and wild-type poliovirus strains.</AbstractText><CopyrightInformation>Copyright Â© 2021 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shaohua</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Vaccine &amp; Serum Institute, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Weiwei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>National Vaccine &amp; Serum Institute, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Shuhua</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Vaccine &amp; Serum Institute, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Huijie</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>National Vaccine &amp; Serum Institute, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhongyang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>National Vaccine &amp; Serum Institute, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiuling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Vaccine &amp; Serum Institute, Beijing, China; Shanghai Institute of Biological Products Co. LTD, China. Electronic address: lixiuling@sinopharm.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Virol Methods</MedlineTA><NlmUniqueID>8005839</NlmUniqueID><ISSNLinking>0166-0934</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Neutralization assay</Keyword><Keyword MajorTopicYN="N">Neutralizing antibody</Keyword><Keyword MajorTopicYN="N">Poliovirus</Keyword><Keyword MajorTopicYN="N">Pseudovirus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>26</Day><Hour>20</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34826519</ArticleId><ArticleId IdType="doi">10.1016/j.jviromet.2021.114376</ArticleId><ArticleId IdType="pii">S0166-0934(21)00315-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle>